Provectus Biopharmaceuticals (OTCMKTS:PVCT) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Earnings & Valuation

This table compares Provectus Biopharmaceuticals and Abbott Laboratories’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Provectus Biopharmaceuticals N/A N/A -$8.15 million N/A N/A
Abbott Laboratories $30.58 billion 4.83 $2.37 billion $2.88 29.02

Abbott Laboratories has higher revenue and earnings than Provectus Biopharmaceuticals.

Analyst Recommendations

This is a summary of current recommendations and price targets for Provectus Biopharmaceuticals and Abbott Laboratories, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Provectus Biopharmaceuticals 0 0 0 0 N/A
Abbott Laboratories 1 2 15 0 2.78

Abbott Laboratories has a consensus price target of $85.94, suggesting a potential upside of 2.82%. Given Abbott Laboratories’ higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than Provectus Biopharmaceuticals.

Profitability

This table compares Provectus Biopharmaceuticals and Abbott Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Provectus Biopharmaceuticals N/A N/A -271.55%
Abbott Laboratories 9.36% 17.26% 7.83%

Insider and Institutional Ownership

0.0% of Provectus Biopharmaceuticals shares are owned by institutional investors. Comparatively, 73.7% of Abbott Laboratories shares are owned by institutional investors. 4.5% of Provectus Biopharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Abbott Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Provectus Biopharmaceuticals has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500.

Dividends

Abbott Laboratories pays an annual dividend of $1.28 per share and has a dividend yield of 1.5%. Provectus Biopharmaceuticals does not pay a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Abbott Laboratories has increased its dividend for 46 consecutive years.

Summary

Abbott Laboratories beats Provectus Biopharmaceuticals on 11 of the 13 factors compared between the two stocks.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing drugs based on halogenated xanthenes for oncology and dermatology indications. Its prescription drug candidates include PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. The company is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.